Popular on eTradeWire
- ForgingBlock has implemented Lightning Network and integrated more cryptocurrencies
- Could Carbonated Drinks Really Be Good For You?
- Get Help About Which Vanity Unit You Need To Add in Your Bathroom
- Get Your Kids Ready for their 1st 5K with help from the Rotary Santa Run
- All you need to know about Ozcrystal, the crystal knob online store
- Local PODS® Moving & Storage to collect toy donations for those in need
- 1MysticFactsCheck Provides The Truth About 1Mystic
- Dr. Artika Tyner's Book Takes Third Place in Children's Literature Contest
- Acclaimed Author Releases Latest Book for Young Readers
- Hacking Hollywood Film Summit and Pitch Fest
Similar on eTradeWire
- SciTech to Present at Biotech Showcase 2020 in San Francisco
- oneservice AG, announces the appointment of Jonathan Mensch as the new President of oneservice Inc. North America
- Sage-N Research Introduces First AI Data System for Biopharmaceutical Proteomics
- NOUS Imaging Announces $6.6 Million in Funding for Brain MRI Software Solution
- 83bar Featured in Pharma Tech Outlook as a Top 10 Marketing Solution Provider for Pharma industry
- AXT Add Alvéole's Unique Cell Biology Platform to Their Life Science Portfolio
- PicoProbe™ Proline Assay Kit (Fluorometric)
- SciTech Development Attending 38th Annual J.P. Morgan Healthcare Conference
- MEDIA ADVISORY: Advances in Regenerative Medicine through Exosome Therapy presented by Dr. Ducan Ross, founder of Kimera Labs at Perpetual Life
- Glutamate Decarboxylase Activity Assay Kit (Fluorometric)
ExpressCells plans to use the $800,000 in proceeds from the first close of its Series A financing to build the commercial and operational infrastructure to sell its knock-in cell lines. This includes operating its lab in Philadelphia and establishing its promotional platform.
"The Series A financing is a significant advance for ExpressCells," said Matt Handel, co-founder and CEO of ExpressCells. "This will allow us to market our novel plasmid technology that will give scientists better cell models for drug discovery and other research purposes. Identification of better lead compounds in the discovery process should result in fewer late-stage failures, reducing the cost of drug development."
More on eTradeWire News
- NCAA Division I university with Mondo track named "Outdoor Track Facility of the Year" by ASBA
- An Offer on a Honda Civic You Can't Miss!
- SelecTech goes FreeStyle with installation at Durfee High School renovation
- Waveband Communications Introduces Accessories for the Motorola XPR7550
- This is a Must Have Ford Escape!
ExpressCells' unique plasmid technology, in combination with CRISPR/Cas9, allows the company to deliver custom cell lines in which a new gene has been successfully inserted into the cell's DNA in 25% of the time required with current technologies. The speed of the process allows the company to insert up to three genes into the same cell line in as few as 3 months. ExpressCells will initially focus on inserting "reporter" genes that code for bioluminescent and fluorescent proteins, allowing scientists to more efficiently visualize intracellular activity. ExpressCells will sell both custom cell lines—each designed to meet the specific requirements of an individual scientist—as well as catalog cell lines with predefined combinations of reporter knock-ins.
Mr. Handel continued: "We appreciate the support of the Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic in leading the Series A. Their shared vision for ExpressCells was instrumental in securing the funding and will be critical in the ongoing success of the company."
More on eTradeWire News
- Innovative LED Sculpture, 'Exhibitionist,' Lights Up Popular Riverside Arts Town, New Hope, PA
- Arson Investigators & OSCR360 Team Network at NYS Arson Investigation Event
- How to Succeed in Competitive Network Marketing
- The Lashe® Announces New Professional Pricing for Lash Aftercare Products
- Steve The Medium Coming To Rude Rangers TV
ExpressCells is a private biotechnology company based in Philadelphia, PA. Our propriety genome editing technology, in combination with CRISPR/Cas9, allows the company to create advanced, knock-in cell lines to enhance drug discovery and other biological research, and shorten the time for delivery of knock-in cell lines by 75% relative to current technologies. Our genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit www.xpresscells.com.
- Pierpoint Introduces Recruitment Resource Outsourcing (RRO) To Accelerate Recruitment Timeline
- Web Series "I Hear You" Screens In Front of A Celebrity Filled Audience
- Santia Deck Makes History; Signs Record Breaking Deal With Highly-Anticipated WFLA
- New Children's Coloring Book—Christmas Toys & Joys
- Solar FlexRack Selected to Supply 105MW Solar Project in North Carolina for Cypress Creek Renewables
- Saturn Vehicle Warranty Alternatives Available from autopom!
- All-Inclusive Braces in Exton Cost Only $3,995
- Dbvisit Announces Release of Dbvisit Standby Snapshot
- Nick Nardello is promoted to Internet Director at Sun Toyota
- Cum Tribute Social Network CumOnPrintedPics.COM Infrastructure Update
- Monitor Your Process Automation System Without A PC
- Homes By Taber Accepting Nominations for 2020 Taber Cares Partners
- Diligence Capital Advisors Opens New Outpost, Leases Center City Philadelphia Office
- Ultrasonic Sensor Designer MaxBotix Inc. Adds Weather-Resistant Wide Beam Sensors to their Catalog
- INI FormStudio™ Now Rated "Avaya Compliant"
- Nonwoven calendering performs crucial steps in manufacturing
- Halfpricesoft.com Has Released The 940 form in ezPaycheck 2019 For End Of Year Processing
- A modern conference table can make you fall in love with meetings again
- Shell Point's 2020 Medical Breakthroughs & Discoveries series to offer free educational seminars
- The Doral Chamber of Commerce Proudly Welcomes REVO Soccer Doral, LLC. as a New Platinum Member